This is a news story, published by ScienceDaily, that relates primarily to SGLT2 news.
For more disease research news, you can click here:
more disease research newsFor more news from ScienceDaily, you can click here:
more news from ScienceDailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like disease research news, you might also like this article about
other diabetes drugs. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest diabetes medication news, other oral diabetes drugs news, disease research news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
diabetes drugsScienceDaily
•
81% Informative
Some diabetes drugs tied to lower risk of dementia, Parkinson's disease.
Study looked at sodium-glucose cotransporter-2 ( SGLT2 ) inhibitors, which are also known as gliflozins.
They lower blood sugar by causing the kidneys to remove sugar from the body through urine.
VR Score
93
Informative language
99
Neutral language
83
Article tone
formal
Language
English
Language complexity
58
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links